Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss. Those legal cases would not be filed against the patient’s doctor because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Ozempic, Wegovy, and Rybelsus Causing Eye Problems, Vision Loss
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic eye problem side effect also applies to Wegovy and Rybelsus.
To read more of this article, click below:
The medical study that found the new Ozempic eye problems side effect was presented in this article, “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide”, which was published on July 3, 2024, by the medical journal JAMA Ophthalmology.
We get an overview of the semaglutide – NAION medical study from this July 3, 2024, STAT news article, “Study links Ozempic to higher risk of eye condition that can cause vision loss”:
A new observational study on [July 3, 2024] reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss….
NAION, sometimes referred to as an “eye stroke,” occurs from a lack of sufficient blood flow to the optic nerve. It typically causes sudden vision loss and, in severe cases, can lead to blindness. There are currently no proven treatments for the condition.
Some information about the increased risk of these Wegovy, Rybelsus, and Ozempic eye problems side effects was provided in this July 3, 2024, MedPage Today article, “Semaglutide May Be Linked to Condition That Causes Blindness”:
Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist (HR 4.28, 95% CI 1.62-11.29, P<0.001)….
Those prescribed semaglutide for overweight or obesity had an over sevenfold higher risk for NAION (HR 7.64, 95% CI 2.21-26.36, P<0.001), a significant cause of blindness…
Over 3 years, the cumulative incidence of NAION were 8.9% and 6.7% in the two semaglutide groups, respectively, versus 1.8% and 0.8% for the non-GLP-1 groups. [emphasis added]
Relevant to this recent finding that Ozempic side effects include eye problems with possible vision loss, we point out that in medical records, NAION is sometimes referred to more simply as an “eye stroke” and because it is a form of “optic neuropathy” (an eye disease category) NAION might be noted in short only as optic neuropathy.
Patients who developed NAION following the use of Ozempic, Wegovy, or Rybelsus may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.
[Read the article in full at source]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages